
Opinion|Videos|May 29, 2024
Diabetes, GLP-1, and Lipid Reduction
Michael Blaha, MD, highlights the potential of GLP-1 agonists in lowering LDL cholesterol, triglycerides, and body weight in patients with diabetes, presenting them as an additional option for reducing cardiovascular risk in this patient population.
Advertisement
Episodes in this series

Advertisement
Latest CME
Advertisement
Advertisement
Trending on HCPLive
1
Kidney Compass: VISIONARY 2-Year eGFR Data in IgA Nephropathy
2
Bimekizumab Data Support Case for Earlier Intervention in HS
3
Q&A: Bimekizumab 2-Year Efficacy by HS Disease Duration, With Raj Chovatiya, MD, PhD
4
A Genetic Signature May Predict Who Gets Sick From CAR T Cell Therapy
5








































































